may 2020 • BMJ

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Tang, Wei and Cao, Zhujun and Han, Mingfeng and Wang, Zhengyan, et al.

DOI: 10.1136/bmj.m1849

Content curation::David Rodrigues

Key message

Ensaio clínico open label o que pode induzir viezes relevantes. Amostra pequena. Hidroxicloroquina não resultou numa probabilidade significativamente maior de conversão negativa do que os cuidados habituais em doentes com COVID19 leve a moderada. Os eventos adversos foram maiores nos doentes a fazer hidroxicloroquina do que nos que não a fizeram.


To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). /n 150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone). /n Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).